Famar Group, a leading European pharmaceutical Contract Development and Manufacturing Organisation (CDMO), has signed a contract manufacturing agreement with GE HealthCare to fill and finish vials of GE HealthCare’s iodine-based contrast media, at its newly acquired site in Homburg, Germany, with commercial supply due to begin in 2028.
This agreement will enable GE HealthCare to expand its manufacturing capacity for Europe-based customers of its iodine-based contrast media, used in Computed Tomography, X-ray, and interventional imaging to enhance visualisation of organs, blood vessels and tissues to support clinical diagnosis. The Homburg site is targeted to provide up to 25 million patient doses, annually, into GE HealthCare’s supply network by 2031.
Famar Group acquired the Homburg site from MiP Pharma in September 2025 and plans to develop it into a multi-customer CDMO platform, strengthening its footprint in high-value dosage forms, expanding its capabilities in aseptic and lyophilised fill and finish and becoming the centre of excellence for sterile supply. With active pharmaceutical ingredients from its Lindesnes facility in Norway, GE HealthCare delivers over 100 million patient doses of contrast media globally every year. Famar’s Homburg site is one of seven Famar Group facilities across Europe, enhancing the company’s ability to serve its customers with flexible, high-quality, and scalable production solutions.
